CombiMatrix Migrates Miscarriage Analysis Microarray Testing to Newer Scanning Panel
February 09 2016 - 6:00AM
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics
company specializing in DNA-based testing services for prenatal and
postnatal developmental disorders and pre-implantation genetic
screening services, announces the migration of its microarray-based
miscarriage testing to the Illumina HumanCytoSNP-12 BeadChip array
platform. CombiMatrix had previously performed miscarriage
analysis on the Illumina CytoSNP-850K BeadChip microarray
platform.
“Our upgrade to this newer platform is expected
to reduce the cost per array by approximately $60 per diagnostic
test, positively impacting gross margins,” said Mark McDonough,
President and Chief Executive Officer of CombiMatrix. “This
is an important strategic move that supports our focus on
microarray testing in the growing in vitro fertilization (IVF) and
miscarriage analysis markets, while reducing costs and furthering
our goal of achieving profitability.
“Upgrading to the CytoSNP-12 is also in keeping
with our commitment to employ the latest in technological
advancements to provide in-depth answers to complex health
questions,” added Mr. McDonough. “The CytoSNP-12 is designed
to provide high-throughput analysis of genetic and structural
variations with substantially better resolution to detect smaller
regions compared to fluorescence in situ hybridization (FISH) or
array comparative genomic hybridization (arrayCGH). Studies
show that it can achieve average SNP call rates and reproducibility
of greater than 99%, and low noise for copy number
measurements.”
About CombiMatrix
Corporation
CombiMatrix Corporation provides valuable
molecular diagnostic solutions and comprehensive clinical support
to foster the highest quality in patient care. CombiMatrix
specializes in prenatal diagnostics, miscarriage analysis for
recurrent pregnancy loss, pediatric genetics and pre-implantation
genetic screening, offering DNA-based testing for the detection of
genetic abnormalities beyond what can be identified through
traditional methodologies. CombiMatrix performs genetic testing
utilizing a variety of advanced cytogenomic techniques, including
chromosomal microarray, standardized and customized fluorescence in
situ hybridization (FISH) and high-resolution karyotyping.
CombiMatrix is dedicated to providing high-level clinical support
for healthcare professionals in order to help them incorporate the
results of complex genetic testing into patient-centered medical
decision making. Additional information about CombiMatrix is
available at www.combimatrix.com or by calling (800) 710-0624.
Safe Harbor Statement under the Private
Securities Litigation Reform Act of 1995
This press release contains forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995. These
statements are based upon our current expectations, speak only as
of the date hereof and are subject to change. All statements, other
than statements of historical fact included in this press release,
are forward-looking statements. Forward-looking statements can
often be identified by words such as "anticipates," "expects,"
"intends," "plans," "goal," "predicts," "believes," "seeks,"
"estimates," "may," "will," "should," "would," "could,"
"potential," "continue," "ongoing," similar expressions, and
variations or negatives of these words and include, but are not
limited to, statements regarding projected results of operations
and management's future business, operational and strategic plans,
recruiting efforts and test menu expansion. These forward-looking
statements are not guarantees of future results and are subject to
risks, uncertainties and assumptions that could cause our actual
results to differ materially and adversely from those expressed in
any forward-looking statement. The risks and uncertainties referred
to above include, but are not limited to: market acceptance of the
HumanCytoSNP-12 BeadChip array platform; our ability to
successfully expand the base of our customers and strategic
partners, add to the menu of our diagnostic tests, develop and
introduce new tests and related reports, expand and improve our
current suite of services, optimize the reimbursements received for
our microarray testing services, and increase operating margins by
improving overall productivity and expanding sales volumes; our
ability to successfully accelerate sales, steadily increase the
size of our customer rosters in both prenatal and developmental
genetic testing markets; our ability to attract and retain a
qualified sales force in wider geographies; our ability to ramp
production from our sales force and our strategic partners; rapid
technological change in our markets; changes in demand for our
future services; legislative, regulatory and competitive
developments; the outcome of pending litigation; general economic
conditions; and various other factors. Further information on
potential factors that could affect our financial results is
included in our Annual Report on Form 10-K, Quarterly Reports of
Form 10-Q, and in other filings with the Securities and
Exchange Commission. We undertake no obligation to revise or update
publicly any forward-looking statements for any reason, except as
required by law.
Company Contact: |
|
Investor Relations Contact: |
Mark McDonough |
|
LHA |
President & CEO, CombiMatrix Corporation |
|
Jody Cain |
(949) 753-0624 |
|
(310) 691-7100 |
|
|
jcain@lhai.com |
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Historical Stock Chart
From Apr 2023 to Apr 2024